A routine CT scan of the heart, the kind ordered to look for clogged arteries, contains far more information than the narrow question it was designed to answer. This review argues that the same single scan can be mined for at least six different risk signals: how much plaque you have, what that plaque is made of, whether a narrowing actually starves the heart of blood, how inflamed the fat hugging your coronary arteries is, how much metabolically active fat sits around the heart, and whether your liver is fatty. Two of these signals are already backed by clinical guidelines. The other four are promising but investigational, with no agreed cutoffs and no proof yet that acting on them changes outcomes.
For decades a coronary CT angiogram, or CCTA, answered one question: is an artery narrowed enough to matter? The big idea in this review is that this framing wastes most of the scan. The same burst of X-rays that maps a narrowing also captures the composition of the plaque, the fat around the vessels, the fat around the heart, and even the liver sitting just below. Software and artificial intelligence can now pull all of it out automatically, turning a plumbing check into something closer to a cardiometabolic physical.
The signals differ sharply in how ready they are for real use. Total plaque volume and specific danger features, low-attenuation “soft” plaque, positive remodelling where a vessel bulges outward to hide a growing plaque, and the napkin-ring sign, predict heart attacks and strokes over and above the degree of narrowing. This is guideline-endorsed territory. So is FFR-CT, a clever trick that simulates blood flow through the reconstructed artery to tell whether a moderate narrowing is actually choking off supply, sparing many patients an invasive test.
The newer and more speculative signals sit outside the artery wall. Inflamed fat sleeving the coronary arteries changes its CT density in a measurable way, and that change tracks vascular inflammation and falls when patients take high-dose statins. The bulk of fat around the whole heart independently predicts coronary disease, atrial fibrillation, and death. And a fatty liver, visible on the same non-contrast scan already used to score calcium, flags systemic metabolic trouble and forecasts worsening plaque.
The honest core of the paper is its restraint. Combining these markers improves the ability to separate high-risk from low-risk people on paper. But the authors repeatedly stress what is missing: standardised thresholds, validation across women and non-White populations, and, above all, evidence that changing treatment based on these numbers actually helps anyone. The four extracoronary and inflammatory markers remain research tools. The promise is real, the plumbing-to-physical upgrade is coming, but the proof that it saves lives has not yet been produced. Until prospective trials close that gap, this is a powerful way to describe risk, not yet a validated way to manage it.
Actionable Insights
The single most transferable, evidence-backed message for a health-conscious reader is that a fatty liver is a cardiovascular problem, not just a liver problem. In a meta-analysis of more than 34,000 adults, imaging-defined fatty liver raised the odds of a combined fatal and non-fatal cardiovascular event by 64 percent (odds ratio 1.64, 95 percent confidence interval 1.26 to 2.13). Severe steatosis roughly doubled the risk (odds ratio about 2.58). To put the magnitude in plain terms: if a baseline group has a 10 percent event rate, an odds ratio of 1.64 corresponds to roughly a 15 percent rate, so about 5 extra events per 100 people. That is a meaningful shift, and liver fat is modifiable through weight loss, exercise, and glycaemic control.
The second message is about statins and inflammation. High-intensity lipid-lowering therapy did not just slow plaque, it arrested progression of total and non-calcified plaque in the LOCATE study, and high-dose statins measurably lowered the inflammation signal in the fat around the arteries. The third is diagnostic self-advocacy: if you have a moderate coronary narrowing, FFR-CT from the existing scan can often settle whether it needs treatment without an invasive procedure.
Context and Source
- Open Access Paper: Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review.
- Authors and institution: Mora, Irannejad, Abbas, Mogga, Iskander, Hubbard, Roy, Lakshmanan, Budoff, and Krishnan (corresponding). Lead institution is Harbor-UCLA Medical Center and The Lundquist Institute for Biomedical Innovation at Harbor-UCLA, Torrance, California, with UCLA Radiology, Los Angeles. Country: United States.
- Journal: Frontiers in Cardiovascular Medicine. Published 04 August 2026.
- Impact evaluation: The impact score of this journal is approximately 2.9 (Journal Impact Factor, 2024/2025 JCR data; some trackers list 3.0), evaluated against a typical high-end range of 0 to 60+ for top general science and against roughly 0 to 40+ for elite specialty cardiology journals such as Circulation and the European Heart Journal. Therefore this is a Low-to-Medium impact journal.